Roche Gets FDA Approval for Vabysmo as Retinal Vein Occlusion Treatment
27 Octubre 2023 - 12:40AM
Noticias Dow Jones
By Adria Calatayud
Roche Holding said it received approval from the U.S. Food and
Drug Administration for Vabysmo as treatment of macular edema
following retinal vein occlusion, the drug's third indication.
The Swiss pharmaceutical giant said Friday that the approval was
based on two late-stage studies that demonstrated early and
sustained vision improvements.
Vabysmo is already approved for so-called "wet" age-related
macular degeneration and diabetic macular edema, Roche said.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 27, 2023 01:25 ET (05:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Roche (QX) (USOTC:RHHBY)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Roche Holdings Ltd AG (QX) (OTCMarkets): 0 recent articles
Más de Roche Holdings Ltd AG (QX) Artículos de Noticias